Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TV 003

Next Previous
Drug Profile

TV 003

Alternative Names: Butantan DV; Dengue Tetravalent Vaccine - Lyophilized formulation; TetraVax-DV Vaccine - Admixture TV003; TetraVax-DV-TV003; TV-003

Latest Information Update: 05 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Developer Butantan Institute; Medigen Vaccine Biologics; Merck & Co; National Institute of Allergy and Infectious Diseases; Panacea Biotec; Serum Institute of India
  • Class Attenuated vaccines; Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dengue
  • Phase I Zika virus infection

Most Recent Events

  • 01 Aug 2025 University of Sao Paulo General Hospital plans a phase III SAFE-BDVARD trial for Rheumatic disorder (In Children, In adolescents, In adults, Prevention) in Brazil (SC, Injection) in August 2025 (NCT07087912)
  • 25 Mar 2025 Butantan institute plans a phase III trial for Dengue (Prevention) in Brazil (SC) (NCT06891950)
  • 12 Dec 2024 Butantan Institute in collaboration with Merck Sharp & Dohme completes a phase II trial in Dengue (Prevention, In adults) in Brazil (SC) (NCT05710224)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top